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Influenza continues to cause widespread disease and death during winter months. In
preclinical studies to evaluate the potential efficacy of drugs and vaccines, influenza
challenge virus is usually instilled into the noses of animals in the form of large liquid
drops. Since inhalation of aerosolized influenza is commonly associated with human
transmission, instillation of challenge virus raises uncertainty about the applicability of
results. In order to compare the challenge methods, we established conditions to generate
influenza aerosols with a mass median aerodynamic diameter (MMAD) of 1µm that
were delivered to mice in a nose-only inhalation system. In this report, we describe
the system and compare the 50% lethal dose (LD50) of instilled and inhaled A/PR/8/34
(PR8) in BALB/c mice. The estimated LD50 for inhaled virus was 8.7 plaque forming units
(PFU) and the mean time to death was 7.7 days, whereas the estimated LD50 for instilled
virus was 51.6 PFU and the mean time to death was 8.2 days. Our results show that
mice are more sensitive to inhaled virus than virus delivered by intranasal instillation.
The murine nose-only inhalation model of influenza infection can be used to infect large
numbers of animals simultaneously with well-characterized, homogenous PR8 bioaerosol
in a controlled and reproducible manner. This model provides the means to evaluate the
efficacy of drug and vaccine candidates against the relevant route of challenge, thereby
providing data that may better predict clinical outcome.
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INTRODUCTION
Influenza is a widespread respiratory disease that results in
approximately 40,000 deaths in the USA and at least one mil-
lion deaths worldwide annually (Dushoff et al., 2006; Osterholm,
2006). To better understand the disease and the prevention of it,
mice, guinea pigs, and ferrets are commonly used in studies of
influenza immunity and pathogenesis. These animal models typi-
cally utilize an intranasal or intratracheal route of virus challenge,
with virus delivered in liquid drops to anesthetized animals so
that natural reflexes to swallow or sneeze are avoided. The vol-
ume administered is substantial, allowing virus to be deposited in
the lower respiratory tract.
Transmission of influenza may occur when virus-containing
aerosol droplets are inhaled into the lung, settle in the upper
respiratory tract, or are sprayed onto the mucous mem-
brane of a recipient when the infected individual sneezes or
coughs. Alternatively, virus on surfaces can be transmitted when
transferred to mucous membranes of a susceptible individual.
Intranasal and intratracheal instillation of virus does not reflect
any of these transmission routes and, therefore, more relevant
administration methods may provide additional information
regarding influenza pathogenesis and immunity. The “natural”
route of influenza infection inman is likely to depend on virus fit-
ness (for example, contact is clearly needed for infection by H5N1
viruses) and environmental circumstances (for example, aerosol
transmission may be more likely in a closed room when the virus
concentration in respirable particles is high). Contact transmis-
sion has been reported as the predominant transmission route
in many studies (Brankston et al., 2007; Jones and Adida, 2011),
but the greater infectivity noted for very small aerosol droplets
in human studies (Teunis et al., 2010), the sustained presence of
virus in respirable droplets in emergency rooms (Blachere et al.,
2009) as well as studies conducted in animal models, suggest
aerosol transmission is an important means by which disease is
spread (Tellier, 2009). Influenza infection by the inhalation route
has been documented inmice (Tate et al., 2008), ferrets (Lednicky
et al., 2010; Tuttle et al., 2010), and human volunteers (Alford
et al., 1966).
Inhalation has historically been considered a relevant route of
influenza infection (Henle et al., 1946), with droplets of various
sizes containing virus transmitted from persons who are sneez-
ing and coughing (Killingley et al., 2012). When virus-containing
aerosols that are ≤10µm in aerodynamic diameter are inhaled,
the virus is more likely to reach the lower respiratory tract, a site
Frontiers in Cellular and Infection Microbiology www.frontiersin.org May 2012 | Volume 2 | Article 74 | 1
CELLULAR AND INFECTION MICROBIOLOGY
Bowen et al. Mouse inhalation model of influenza
at which virus replication is very efficient (Knight, 1980). Since
some level of technical expertise is required for animal studies
that include challenge with an aerosolized influenza preparation,
inhalation studies are rarely performed. Instead, intranasal and
intratracheal instillation of influenza is routinely used to chal-
lenge animals when testing the efficacy or new vaccines and
antiviral drugs. Intranasal and intratracheal instillation often
results in a non-homogenous distribution of virus in the lungs
that can affect early intrapulmonary distribution as well as viral
retention and clearance kinetics (Nayak et al., 1965; Driscoll et al.,
2000).
Whole-body inhalation systems are often used to expose mice
to aerosolized virus, however, these systems generally require
large amounts of challenge material because of their large inter-
nal volumes and high operating volumetric flow rates (Wong
et al., 2010). Additionally, animals that are challenged in whole-
body inhalation systems receive extensive dermal and ocular
doses which may exacerbate the natural progression of influenza.
Furthermore, mice that are challenged as a group may huddle
together resulting in unequal inhaled doses (IDs). Even mice that
are singly challenged in a whole-body inhalation system may curl
up, thus effectively shielding their nares and adversely affecting
ID. Animals that are challenged with influenza in a nose-only
inhalation system are more likely to be challenged with a uniform
dose and do not have the potential of carrying infectious virus on
their fur.
Individual nasal nebulizers have been engineered to deliver
virus or live, attenuated vaccine in small droplets of defined
size to mice and ferrets (Smith et al., 2011, 2012). This device,
(AeroLife or a mass campaign nebulizer), is very easy to use
but may not consistently deliver the expected dose if the person
administering the virus is not adequately trained or experienced.
In contrast, nebulizers and delivery methods in which air flow
and particle size are controlled precisely can be used in the lab-
oratory setting to provide consistent delivery of dose, yielding
reproducible results in a number of infectious disease models
(Bakker-Woudenberg, 2003), including anthrax (Loving et al.,
2007), tuberculosis (Williams et al., 2000), and influenza (Gustin
et al., 2011). In this report, we describe the characterization of a
murine model of influenza infection using a nose-only inhalation
challenge system, and compare the LD50 of instilled and inhaled
virus in BALB/c mice.
MATERIALS AND METHODS
MICE
BALB/c mice were purchased from The Jackson Laboratories (Bar
Harbor, ME) and housed at Center for Biologics Evaluation and
Research (CBER). Mice that were subjected to nose-only inhala-
tion challenge were shipped to Southern Research Institute (SR)
approximately one week before the start of the study. Cage size
and animal care conformed to the guidelines of the Guide for
the Care and Use of Laboratory Animals, the US Department of
Agriculture through the AnimalWelfare Act, and to the applicable
Standard Operating Procedures (SOPs) of CBER and SR.
Mice were challenged by instillation at CBER, and inhalation at
SR following procedures approved by the respective Institutional
Animal Care and Use Committees. On Day 6, each mouse at SR
was uniquely identified by an implantable micro-identification
device (IPTT-300 Chip; Biomedic Data Systems Inc., Seaford, DE)
inserted subcutaneously between the shoulder blades. The micro-
identification chips also provided body temperature data and if
the chip was not responding, temperatures were taken manually.
On Day 0 of the inhalation and instillation studies, the mice were
approximately 15 weeks of age and weighed between 19.7 and
26.1 g.
VIRUS
Mouse-adapted A/PR/8/34 (PR8) was grown in 10–11 day-old-
chicken eggs at 33◦C for 60–72 h. The allantoic fluid of each
egg was then harvested into 50ml tubes and cellular debris pel-
leted. The supernatant was snap-frozen and stored at −80◦C. On
the day of inoculation, virus dilutions were made in phosphate
buffered saline (PBS); each dilution was kept at 4◦C prior to the
infection.
The virus titer was determined by plaque assay as previously
described (Xie et al., 2007). Briefly, confluent layers of MDCK
cells were prepared in sterile 6-well plates. After washing the cells
in serum-free medium, 1mL of each virus dilution was added to
duplicate wells, and the plates incubated at 37◦C for 1 h before
removal of the inoculum and addition of an agarose overlay.
The plates were incubated for three days before the cells were
fixed with cold acetone. After removal of the overlay the cells
were stained with crystal violet, and the plaques counted after
washing the well. To determine the number of plaque forming
units (PFU), whole lungs were homogenized in 2mL using ster-
ile glass Dounce homogenizers, and the cellular debris pelleted
by centrifugation. The supernatant was divided into two aliquots,
snap-frozen, and stored at −80◦C. Immediately prior to per-
forming the plaque assay, the lung homogenate was thawed, and
10-fold dilutions made in PBS. Since the undiluted sample was
usually toxic to the cells, the lowest dilution added to the mono-
layers was 1/10. Alternatively, lung homogenates were titrated in
a 50% tissue culture infectious dose (TCID50) assay as previously
described (Ottolini et al., 2005).
INHALATION CHALLENGE SYSTEM
The murine inhalation challenge system consisted of six compo-
nents: a compressed air source, a bioaerosol delivery line, a 24-
port radial nose-only inhalation challenge plenum, a bioaerosol
characterization platform, an air handling station, and an exhaust
platform. The bioaerosol delivery line consisted of a Collison
3-Jet Nebulizer (BGI Inc., Waltham, MA), a radial in-line
aerosol mixer (In-Tox Products, LLC, Albuquerque, NM), and
a filtered air passive dilutor. The radial nose-only inhalation
challenge plenum (In-Tox Products) was fitted with Positive
Flow-By™ restraint tubes (In-Tox Products) and isoaxial sam-
ple collection ports that interfaced with the bioaerosol char-
acterization platform. The bioaerosol characterization platform
included air sampling impingers, Model 7541 (Ace Glass, Inc.,
Vineland, NJ), and an Aerosol Particle Sizer™ Spectrometer
(APS, TSI Inc., Shoreview, MN). The air handling station inter-
faced with the bioaerosol delivery line, the bioaerosol charac-
terization platform, and the exhaust platform and consisted of
computer regulated gas flow and pressure controllers (Alicat
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Scientific, Inc., Tucson, AZ). The exhaust platform consisted of
HEPA filters, a differential pressure magnehelic, and a vacuum
pump. The bioaerosol delivery line, inhalation challenge plenum,
and bioaerosol characterization platform were placed inside a
SterilGARD® III Advance™ (Baker Company, Sanford, ME) bio-
logical safety cabinet (BSC). The inhalation challenge plenumwas
maintained at a slightly negative pressure relative to the BSC.
The BSC was maintained at a slightly negative pressure with
respect to the Animal Biosafety Level-2 laboratory. Temperature
and relative humidity within the inhalation challenge plenum
were monitored using a Humidity Temperature Meter (Omega
Engineering, Stamford, CT). Inhalation challenge plenum oxy-
gen levels were monitored continuously during all challenges
with a Model 5800 Intelligent Oxygen Monitor (Hudson RCI,
Durham, NC).
INHALATION CHALLENGE
On three consecutive days prior to inhalation challenge, mice
were trained in the nose-only inhalation restraint tubes. On the
first day of training mice were loaded into nose-only inhalation
restraint tubes and placed in a horizontal position for approx-
imately 15min. On the second and third days, animals were
loaded into nose-only restraint tubes and connected to a ven-
tilated plenum for approximately 30min. Mice were monitored
continuously during training to confirm that orientation was
correct and respiration was not dyspneic.
On the day of challenge (Day 0), mice were placed in the nose-
only inhalation restraint tubes and connected to the inhalation
challenge plenum using Positive Flow-By™ nose cones (In-Tox
Products). An air sampling impinger and the APS were connected
to individual sampling ports on the plenum using conductive tub-
ing. The Collison 3-Jet Nebulizer was filled with nebulizer stock
suspension and connected to the bioaerosol delivery line. A pre-
spray nebulizer suspension sample was collected for analysis by
plaque assay. The start of the challenge period (T = 0) began once
the nebulizer was activated and set at 30 psi. All groups of mice
(n = 8) were challenged with PR8 aerosol or vehicle (PBS) for
30min. Following inhalation challenge, the mice were removed
from the nose-only inhalation restraint tubes and returned to
their cages for monitoring.
INSTILLATION CHALLENGE
Groups of mice (n = 8) were anesthetized by exposure to 3%
isoflurane in the presence of 3% O2 and inoculated with 30µL
of PR8 diluted in PBS, by applying droplets of the suspension to
both nares.
ANIMAL MONITORING
All mice were observed twice daily during quarantine and study
periods for signs of moribundity and mortality. Detailed clin-
ical observations were performed daily beginning on Day 2
and continued through the end of the study on Day 14. Body
weights were obtained on Day 6 for randomization and then
daily beginning on Day 2 through the end of the study on Day
14. Animals that were moribund prior to Day 14 were eutha-
nized. On Day 14, all surviving mice were euthanized via CO2
asphyxiation.
STATISTICAL ANALYSES
Group means and standard deviations were calculated when
appropriate for body weights and body temperatures. Statistical
analyses for body weight data and body temperature data were
performed using the Provantis automated data collection system
(Instem, Staffordshire, UK). The mean, standard deviation, and
coefficient of variance were calculated for aerobiology data using
EXCEL (Microsoft Excel 2003, Redmond, WA) or SigmaPlot
(Systat Software, Inc., San Jose, CA) when appropriate. Statistical
differences between the dose groups were evaluated using pro-
bit analysis. The independent variable for the probit analysis was
dose, and the dependent variable was survival.
RESULTS
PARTICLE SIZE DISTRIBUTION
PR8 particle size distribution, reported as mass median aerody-
namic diameter (MMAD), count median aerodynamic diameter
(CMAD), and their respective geometric standard deviations
(GSDs), was determined by the analysis of aerosol samples col-
lected from the inhalation challenge plenum by the Aerodynamic
Particle Sizer (APS). An APS Diluter, fitted with a 1:100 cap-
illary tube, was used to reduce the total number of particles
sampled. All APS samples were 20 s in duration and collected
at approximately T = 15min of the challenge. The MMAD was
1.0µm and the GSD was 1.8. This confirmed that the aerosol
was respirable and maximized for pulmonary-alveolar deposi-
tion in mice, with MMAD < 3.5µm (Schlesinger, 1985). The
CMAD was 0.7µm and the GSD was 1.3. Although the parti-
cle size distribution was polydisperse by definition [GSD > 1.2
(Mercer, 1973)], both the mass and count GSDs were less than
2.0. Therefore, the total deposition of aerosol in the respira-
tory tract of the mice would not be substantially different from
a monodisperse aerosol (McClellan, 1989). Representative plots
of the mass and count cumulative particle size distributions are
shown in Figure 1.
BIOAEROSOL CONCENTRATION
Based on data from the aerosol concentration (AC) characteriza-
tion tests, target nebulizer suspension concentrations were pre-
pared. Immediately before inhalation challenge, pre-spray sam-
ples of PR8 nebulizer suspension were collected and the actual
concentrations were determined by plaque analysis. Pre-spray
PR8 nebulizer suspension concentrations were 0, 8500, 180,000,
1,400,000, and 3,200,000 PFU/mL, respectively (Table 1).
The concentration (PFU/L) of PR8 in the aerosol was deter-
mined from plaque assay of air sampling impinger samples col-
lected from the inhalation challenge plenum. AC was calculated
as: AC = (Ci • Vi)/(Qi • Ts), where Ci is the impinger concen-
tration (PFU/mL), Vi is the final volume (mL) of the PBS in the
impinger,Qi is the impinger volumetric flow rate (L/min), and Ts
is the sample collection duration (min). Impingers were prepared
with 20mL PBS. Target bioaerosol concentration was varied by
increasing nebulizer suspension concentration. All impinger sam-
ples were collected for 30min using a critical pressure flow of
approximately 6 L/min. The concentrations of live virus in the
aerosol (AC) for each of the nebulizer suspensions listed, were: 0,
7.6, 96, 860, and 1200 PFU/L, respectively.
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FIGURE 1 | Distribution of particle size mass and count in PR8
aerosols. APS samples collected from the challenge plenum were used
to determine, (A) the distribution of particle size mass; dM is the mass of
the particles collected in the range (total mass) and dlogDp is the difference
in the log of the channel width; and (B) the distribution of particle size
count; dN is the number of the particles collected in the range
(total concentration), and dlogDp is the difference in the log of the channel
width.
Table 1 | PR8 bioaerosol concentration.
Group Virus concentration Virus concentration Impinger final Impinger flow Sample collection Virus concentration
in the nebulizer in the impinger volume rate duration in the Aerosol
(PFU/mL) (PFU/mL) (mL) (L/min) (min) (PFU/L)
1 0 0 15.5 5.91 30 0
2 8500 9 15.0 5.96 30 7.6
3 180,000 1100 15.0 5.75 30 96
4 1,400,000 10,000 15.0 5.80 30 860
5 3,200,000 14,000 15.0 6.00 30 1200
COMPARISON OF LUNG DEPOSITION OF INHALED AND
INSTILLED VIRUS
Groups of eight mice were challenged with PR8 as an aerosol
(nose-only) and liquid suspension at the highest dose used in the
LD50 study i.e., 1000 PFU instilled, and 1200 PFU/L inhaled for
30min. Using a minute ventilation rate of 0.060 L/min (Flandre
et al., 2003), the ID calculated was 2200 PFU. To determine how
much virus was deposited in the lower respiratory tract, all the
mice were euthanized within 15min of challenge, and lungs
prepared for virus titration. The sensitivity of the plaque assay
precluded measurement of a virus titer in all lungs of the mice
inoculated with aerosol. Virus was measured in only one of these
eight mice, with a titer of 120 PFU/lung. The deposition fraction
measured for this one animal was 5.5%, a value that is pre-
dicted from studies comparing efficiency of deposition for aerosol
particles of different MMAD (Schlesinger, 1985). To be able to
compare pulmonary deposition of inhaled and instilled virus,
we determined virus titers in lungs as well as the virus inocu-
lum by a more sensitive TCID50 assay. The TCID50 results in
Table 2 reflect this greater sensitivity (one PFU is equivalent to
approximately 102 TCID50 of PR8). While the amount of virus
inhaled and instilled was similar, the amount of instilled PR8
measured in the lungs was almost 10-fold greater than when virus
was inhaled. While additional studies with greater inoculation
doses are needed to confirm deposition efficiency in our system,
these results show that deposition of virus into the lower respira-
tory tract was more efficient when virus was instilled intranasally
under anesthesia.
COMPARISON OF INHALATION AND INSTILLATION LD50
Five groups of eight BALB/c mice were infected with virus by
inhalation of PR8 at the ACs given in the previous section. ID
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Table 2 | PR8 deposition in lungs.
Virus concentration
(log10 TCID50 per mouse)
Percent deposited
Administered Lung GMT (SD)
Inhaled 5.3 2.5 ± 0.7 0.14
Instilled 5.0 3.3 ± 0.3 2.20
was calculated using the following equation: ID = AC • Vm • Tc ,
where AC is the virus AC (PFU/L), Vm is the murine minute
ventilation (L/min), and Tc is the inhalation challenge duration
(min). Based on data for restrained BALB/c mice of similar weight
to those used in this study, a minute ventilation of 0.060 L/min
(Flandre et al., 2003), was used to calculate IDs of 0, 14, 170,
1500, and 2200 PFU for mice in Groups 1–5 of the inhalation
LD50 study, respectively. Thirty-one of 32 mice were found dead
or euthanized in moribund condition by Day 12 in the inhala-
tion study. A survival plot is shown in Figure 2A. The mean time
to death for mice challenged with PR8 aerosol was 7.7 days. The
inhalation LD50 formice challenged with PR8 virus was estimated
to be 8.7 PFU (Figure 3A). Since there was only one surviving
mouse, 95% confidence intervals could not be calculated.
Five groups of eight female BALB/c mice were infected with
PR8 virus by intranasal instillation. Mice were anesthetized and
inoculated with 30µL PR8 diluted in PBS to yield instillation
doses of 1.6, 8, 40, 200, and 1000 PFU/mouse. Nineteen of 40mice
were found dead or euthanized in moribund condition by Day 9.
A survival plot is shown in Figure 2B. The instillation LD50 for
mice challenged with PR8 virus was estimated to be 51.6 PFU,
with 95% confidence interval of 20.7–119.1 PFU (Figure 3B).
The mean time to death for mice challenged with PR8 virus by
intranasal instillation was 8.2 days.
Body weight was recorded daily during the inhalation and
instillation studies. Significant weight loss in the highest dose
groups was observed two days after both inhalation and instil-
lation of PR8 (Figure 4). There was a trend toward recovery
to baseline weights for surviving mice, however, recovery after
inhalation was delayed by 2–3 days compared with the mice that
were inoculated by instillation (increased weights measured on
days 8 or 9). Signs of disease such as lack of grooming, hunched
posture, squinting, tachypnea, and dyspnea were observed after
both inhalation and instillation in a dose-dependent manner.
Temperature was only measured in the inhalation group. The
degree of hypothermia was similar for all mice challenged with
doses ≥170 PFU, but mice challenged at the lowest dose experi-
enced significantly less hypothermia (Figure 5) and weight loss
(Figure 4A), even though most mice in this group died.
DISCUSSION
In this report, we identify differences in influenza morbidity and
mortality in BALB/c mice that were challenged with PR8 by
inhalation of aerosol particles and by intranasal instillation of
liquid drops. Less PR8 virus in the nose-only inhalation model
resulted in death than intranasal instillation, with an estimated
inhalation LD50 of approximately 8.7 PFU, while the estimated
FIGURE 2 | (A) Inhalation and (B) instillation survival plots for mice exposed
to PR8. A key indicating color code for each dose group is provided on the
figure.
instillation LD50 was 51.6 PFU. This result concurs with past stud-
ies comparing instillation and inhalation routes that show higher
doses of an H3N2 virus are required for infection when applied
as liquid drops intranasally (Larson et al., 1976), suggesting this
finding is generally applicable.
The severity and frequency of most clinical signs after either
inhalation or instillation increased with dose, suggesting that dis-
ease is proportional to the number of virus particles. It was,
therefore, somewhat surprising that mortality was greatest in the
animals exposed to aerosolized virus as titration of virus immedi-
ately after inoculation showed that the amount of virus deposited
in the lungs was only a small proportion of the ID. In our model
the amount of virus deposited into the lungs was = 7% of the ID,
a deposition efficiency demonstrated previously for mice inocu-
lated with monodisperse aerosol particles having mean diameter
of approximately 1µm (Schlesinger, 1985). This was less effi-
cient than deposition of instilled virus, and yet mice exposed
to inhaled virus were more sensitive to death. We, therefore,
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FIGURE 3 | Probit analysis to determine LD50 for (A) inhaled, and
(B) instilled PR8. Dashed lines show 95% confidence interval for the
analysis. Since >50% of mice died in the lowest aerosol challenge group,
95% confidence intervals are not shown for inhaled PR8.
hypothesized that the region of the lung or cell type infected by
aerosolized virus, rather than the overall virus dose, accounts for
the difference in lethality.
Infection with mouse-adapted PR8 is known to result in viral
pneumonia (Yetter et al., 1980), and animal experiments (Loosli
et al., 1975), as well as immunostaining of lung sections from
infected people (Uiprasertkul et al., 2005; Basu et al., 2011), show
infection of Type II pneumocytes in alveoli as a primary site of
replication. Since we generated aerosol droplets of a size that have
the ability to reach the alveoli, we predict that this form of deliv-
ery allows more efficient infection of these cells in the alveoli,
resulting in a lower LD50 than virus instilled into the nares as a
liquid suspension. Even though the latter administration is con-
ducted under anesthesia and the bulk of the inoculum reaches the
lower respiratory tract (Larson et al., 1976), it is likely that these
large drops would be retained in the bronchioles where virus can
be eliminated after binding to mucins (Rogers, 2003) or inacti-
vated by a number of other innate soluble or cellular mechanisms.
This may include inactivation by collectins such as surfactant pro-
tein D, alone or through activation of neutrophils (Hartshorn
et al., 1994), inactivation by phosphatidylglycerol (Numata et al.,
2012), or removal by macrophages (Wang et al., 2012). Our future
studies will determine whether there is differential distribution of
infected cells in the lower respiratory tract after inhalation and
instillation challenge.
FIGURE 4 | Change in body weight for groups of mice challenged with
PR8 by (A) inhalation, and (B) instillation. Mice in each group (n = 8)
were weighed individually on each day after challenge. Each graph shows
the group mean change in weight relative to the Day 0 (inhalation) and Day
1 (instillation) baseline body weights. Error bars are ± standard deviation of
the mean.
FIGURE 5 | Change in body temperature for groups of mice challenged
with PR8 aerosol. Temperatures of mice in each group (n = 8) were
recorded individually on each day after challenge. The graph shows group
mean change in temperature relative to the baseline temperature collected
prior to challenge on Day 0 Error bars are ± standard deviation of the mean.
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Immune responses such as HA-specific antibodies that block
binding of virus particles to cellular receptors and NA-specific
antibodies that limit access of virus to the epithelium by pre-
venting influenza’s release from mucins, play a key role in
preventing disease and death following exposure to influenza.
While mucosal antibodies of the IgA isotype prevent infec-
tion in the upper respiratory tract, IgG that transudates into
brochi and alveoli restricts virus replication in the lower res-
piratory tract (Renegar et al., 2004). It is not known whether
the effective titer of HA- or NA-specific antibodies is the same
for inhaled and instilled virus. Our future studies will examine
whether antibody and cell-mediated immune responses pro-
vide equivalent protection against aerosol and liquid forms of
virus.
In conclusion, this study demonstrated that challenge of
BALB/c mice with PR8 by nose-only inhalation resulted in more
severe disease, and death at a lower dose, than virus instilled into
the nose as a liquid formulation.Mice challenged with aerosolized
influenza may consequently provide additional data to support
the safety and efficacy of drugs and vaccines that are currently
under development.
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